Table 1.
Characteristics of patients and baseline data
| Patient | Gender | Gene abnormities | Age (year) | Status at HSCT | Donor age (year) type, gender, HLA match | KIR/KIR ligand mismatch | Conditioning regimen | CD34+ (×106/kg recipient weight) | Neutrophil engraftment post HSCT | platelet engraftment post HSCT | aGVHD | cGVHD | Time to relapsed after HSCT (months) | Extramedullary disease when relapse | BM blasts at relapse (%) | Salvage therapies before blinatumomab | Time from relapse to the first blinatumomab (days) | BM blasts at blinatumomab | Weight at blinatumomab (kg) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | F | None | 27 | MRD-negative CR1 | 23, F, 5/10 sister | C2 | MAC | 8.5 | 11 | 12 | Liver, GI tract | Mild | 8.8 | No | 38.5 | No | 13 | 38.5% | 46 |
| #2 | F | E2A-PBX1 | 52 | MRD-negative CR1 | 25, F, 5/10 daughter | No | MAC | 6.0 | 13 | 13 | Skin | Mild | 10.7 | No | 5.5 | No | 21 | 37.5% | 59 |
| #3 | M | None | 22 | MRD-negative CR1 | 54, M, 5/10 father | C2 | MAC | 3.1 | 11 | 11 | Skin | Mild | 19.0 | No | 69.0 | VICP | 35 | 61.5% | 62 |
| #4 | M | None | 32 | MRD-negative CR1 | 31, M, 5/10 brother | No | MAC | 10.6 | 12 | 15 | No | No | 9.5 | Testicles | 18.9 | VMCP | 18 | 6.0% | 58 |
aGVHD, acute graft-versus-host disease; BM, bone marrow; cGVHD, chronic graft-versus-host disease; CR, complete remission; F, female; GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; KIR, killer-cell immunoglobulin-like receptor; M, male; MAC, myeloablative conditioning; MRD, minimal residual disease; VICP, vincristine, idarubicin, cyclophosphamide and prednisone; VMCP, vincristine, melphalan, cyclophosphamide and prednisone.